Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Asset Writedowns and Impairment (2018 - 2023)

Historic Asset Writedowns and Impairment for iBio (IBIO) over the last 7 years, with Q2 2023 value amounting to $300000.0.

  • iBio's Asset Writedowns and Impairment fell 8295.45% to $300000.0 in Q2 2023 from the same period last year, while for Jun 2024 it was $251000.0, marking a year-over-year decrease of 9025.62%. This contributed to the annual value of $3.1 million for FY2024, which is 8268.16% down from last year.
  • As of Q2 2023, iBio's Asset Writedowns and Impairment stood at $300000.0, which was down 8295.45% from -$49000.0 recorded in Q1 2023.
  • In the past 5 years, iBio's Asset Writedowns and Impairment ranged from a high of $1.8 million in Q2 2022 and a low of -$49000.0 during Q1 2023
  • For the 4-year period, iBio's Asset Writedowns and Impairment averaged around $562166.7, with its median value being $398500.0 (2020).
  • Examining YoY changes over the last 5 years, iBio's Asset Writedowns and Impairment showed a top increase of 8295.45% in 2023 and a maximum decrease of 8295.45% in 2023.
  • Over the past 4 years, iBio's Asset Writedowns and Impairment (Quarter) stood at $497000.0 in 2020, then crashed by 39.64% to $300000.0 in 2021, then surged by 88.33% to $565000.0 in 2022, then tumbled by 46.9% to $300000.0 in 2023.
  • Its Asset Writedowns and Impairment was $300000.0 in Q2 2023, compared to -$49000.0 in Q1 2023 and $565000.0 in Q4 2022.